<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448731</url>
  </required_header>
  <id_info>
    <org_study_id>DERMIA</org_study_id>
    <secondary_id>2017-004413-98</secondary_id>
    <nct_id>NCT03448731</nct_id>
  </id_info>
  <brief_title>Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)</brief_title>
  <acronym>DERMIA</acronym>
  <official_title>Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion CRIS de Investigación para Vencer el Cáncer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion CRIS de Investigación para Vencer el Cáncer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the
      potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of
      doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth
      Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the
      present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the
      prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with
      anti-EGFR in combination with chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in the prevention of skin toxicity</measure>
    <time_frame>During 6-week skin treatment</time_frame>
    <description>Monitoring of skin toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Change in Dermatology Life Quality Index (DLQI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Number of adverse events per patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Skin Toxicity</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 50 mg p.o. daily during 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 50Mg Tablet</intervention_name>
    <description>Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman at least 18 years old

          -  Capable of understanding, signing and dating an informed consent approved by an
             Independent Ethics Committee (IEC)

          -  Histologically confirmed adenocarcinoma of the colon or rectum in patients with
             initially unresectable metastatic (M1) disease

          -  Wild-type RAS tumour status confirmed before study inclusion at local institution

          -  Patients who have a treatment plan based on FOLFOX + anti-EGFR or FOLFIRI + anti-EGFR,
             as first-line treatment of mCRC

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Adequate bone marrow function: neutrophils ≥1.5 x109/L; platelets ≥100 x109/L;
             haemoglobin ≥9 g/dL

          -  Hepatic, renal and metabolic function as follows: Total bilirubin count ≤1.5 x upper
             limit of normal (ULN), Alanine aminotransferase (ALT) and Aspartate aminotransferase
             (AST) &lt;5 x ULN; Renal function, calculated as creatinine clearance or 24-hour
             creatinine clearance ≥50 mL/min; Magnesium &gt; lower limit of normal (LLN)

        Exclusion Criteria:

          -  History of prior or concurrent central nervous system (CNS) metastases

          -  History of another primary cancer, except: curatively treated in situ cervical cancer,
             or curatively resected non-melanoma skin cancer, or other primary solid tumour
             curatively treated with no known active disease present and no treatment administered
             for ≥5 years before treatment initiation

          -  Known hypersensitivity to tetracyclines

          -  Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic
             colorectal carcinoma

          -  Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before
             metastatic disease was diagnosed

          -  Unresolved toxicities of a previous systemic treatment that, in the opinion of the
             investigator, cause the patient unfit for inclusion

          -  Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab),
             antivascular endothelial growth factor (VEGF) or treatment with small molecule EGFR
             inhibitors (e.g., erlotinib)

          -  Prior hormonal therapy, immunotherapy or approved or experimental antibody/proteins
             ≤30 days before inclusion.

          -  Significant cardiovascular disease including unstable angina or myocardial infarction
             within 12 months before initiating study treatment or a history of ventricular
             arrhythmia

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT)

          -  Treatment for systemic infection within 14 days before the start of study treatment

          -  Acute or subacute intestinal occlusion and/or active inflammatory bowel disease or
             other bowel disease that causes chronic diarrhoea (defined as grade ≥ 2 diarrhoea
             according to Common Terminology Criteria for Adverse Events (CTCAE)

          -  Clinically significant peripheral sensory neuropathy

          -  Evidence of previous acute hypersensitivity reaction, of any grade, to any component
             of the treatment

          -  History of Gilbert disease or known dihydropyrimidine deficiency syndrome

          -  Recent gastroduodenal ulcer to be active or uncontrolled

          -  Recent pulmonary embolism, deep vein thrombosis, or other significant venous event

          -  Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled
             anticoagulation therapy

          -  Recent major surgical procedure, open biopsy, or significant traumatic injury not yet
             recovered from prior major surgery

          -  History of any disease that may increase the risks associated with study participation
             or may interfere with the interpretation of study results.

          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,
             chronic active hepatitis B infection

          -  Any disorder that compromises the patient's ability to provide written informed
             consent and/or comply with study procedures

          -  Any investigational agent within 30 days prior to inclusion

          -  Pregnant or breastfeeding woman

          -  Surgery (excluding diagnostic biopsy or placement of a central venous catheter) and/or
             radiotherapy within 28 days prior to inclusion in the study.

          -  Male or female of childbearing age who do not agree with taking adequate contraceptive
             precautions, i.e. use contraception double barrier (e.g. diaphragm plus condoms) or
             abstinence during the course of the study and for 6 months after the last
             administration of study drug for women and 1 month for men

          -  The patient is unwilling or unable to meet the requirements of the study.
             Psychological, geographical, familial or sociological conditions that potentially
             prevent compliance with the study protocol and follow-up schedule. These conditions
             should be discussed with the patient before inclusion in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Ramirez-Daffós, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta del Mar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Moreno</last_name>
    <phone>+34918166804</phone>
    <email>ana.moreno@apices.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Punta Europa</name>
      <address>
        <city>Algeciras</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Manuel Rodríguez García, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Manuel Rodríguez García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Ramírez Daffos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patricia Ramírez Daffos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerto Real</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Rubiales Trujillano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandra Rubiales Trujillano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Ceballos Barbancho, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Ceballos Barbancho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Cecilio</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz González Astorga, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz González Astorga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matilde Bolaños Naranjo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matilde Bolaños Naranjo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Encarnación Jiménez Orozco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Encarnación Jiménez Orozco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan José Reina Zoilo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juan José Reina Zoilo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

